Search

Displaying results 3341 - 3350 of 8171 in total
  1. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    [F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones.

  2. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.

  3. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  4. Drug

    Acetylcholine

    go.drugbank.com/drugs/DB03128
    ApprovedInvestigational

    It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.

  5. Drug

    Phenylacetic acid

    go.drugbank.com/drugs/DB09269
    Approved

    Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.

  6. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].

    Mixtures: D-ARTEPP, D-ARTEPP DISPERSIBLECategories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  7. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

  8. Drug

    AKN-028

    go.drugbank.com/drugs/DB12746
    Investigational

    AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.

  9. Drug

    CAN-106

    go.drugbank.com/drugs/DB18389
    Investigational

    CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.

  10. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side